{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:36:10Z","timestamp":1788363370346,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"NIH\/NCI","award":["R01CA175318"],"award-info":[{"award-number":["R01CA175318"]}]},{"name":"NIH\/NCI Flow Cytometry","award":["P30CA072720-5924"],"award-info":[{"award-number":["P30CA072720-5924"]}]},{"name":"Biorepository and Histopathology","award":["P30CA072720-5919"],"award-info":[{"award-number":["P30CA072720-5919"]}]},{"name":"Shared Resources of the Rutgers-Cancer Institute of New Jersey"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jconrel.2019.09.006","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T11:21:39Z","timestamp":1567768899000},"page":"273-287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Bioengineered adipose-derived stem cells for targeted enzyme-prodrug therapy of ovarian cancer intraperitoneal metastasis"],"prefix":"10.1016","volume":"311-312","author":[{"given":"Obeid M.","family":"Malekshah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddik","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0028-5870","authenticated-orcid":false,"given":"Alireza","family":"Nomani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niket","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Javidian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Goedken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Polunas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Louro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4611-7469","authenticated-orcid":false,"given":"Arash","family":"Hatefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2019.09.006_bib0005","doi-asserted-by":"crossref","first-page":"viii36","DOI":"10.1093\/annonc\/mdx450","article-title":"Front-line therapy of advanced epithelial ovarian cancer: standard treatment","volume":"28","author":"Marth","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0010","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ygyno.2013.12.001","article-title":"Ovarian cancer stem cells: are they real and why are they important?","volume":"132","author":"Shah","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0015","first-page":"4613","article-title":"Salvage chemotherapy for ovarian carcinoma recurring during or after consolidation chemotherapy with paclitaxel","volume":"31","author":"Miyoshi","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0020","first-page":"7","article-title":"Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status","volume":"14","author":"Hjortkjaer","year":"2018","journal-title":"Cancer. Treat. Res. Commun."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0025","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S1470-2045(18)30372-3","article-title":"Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Chekerov","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0030","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/JCO.2003.02.091","article-title":"Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer","volume":"21","author":"Bodurka","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0035","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00280-017-3468-5","article-title":"Combination chemotherapy with irinotecan and gemcitabine for taxane\/platinum-resistant\/refractory ovarian and primary peritoneal cancer: a multicenter phase I\/II trial (GOGO-Ov 6)","volume":"80","author":"Yoshino","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0040","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2000.18.17.3093","article-title":"Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer","volume":"18","author":"Gordon","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0045","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00280-017-3363-0","article-title":"A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)","volume":"80","author":"Shoji","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0050","doi-asserted-by":"crossref","first-page":"352","DOI":"10.5468\/ogs.2018.61.3.352","article-title":"Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer","volume":"61","author":"Shin","year":"2018","journal-title":"Obstet. Gynecol. Sci."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0055","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1080\/01443615.2017.1290056","article-title":"Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer","volume":"37","author":"Bozkaya","year":"2017","journal-title":"J. Obstet. Gynaecol."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0060","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0090-8258(03)00399-8","article-title":"Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer","volume":"90","author":"Markman","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0065","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ygyno.2005.10.013","article-title":"The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer","volume":"100","author":"Matsumoto","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0070","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1002\/cam4.1631","article-title":"A novel chemotherapeutic protocol for peritoneal metastasis and inhibition of relapse in drug resistant ovarian cancer","volume":"7","author":"Sarkar","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0075","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1634\/stemcells.2007-0054","article-title":"The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities","volume":"25","author":"Ponte","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/j.jconrel.2019.09.006_bib0080","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1517\/17425255.4.9.1153","article-title":"Modifications of human carboxylesterase for improved prodrug activation","volume":"4","author":"Hatfield","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0085","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/0929867033368619","article-title":"Lessons learned from the irinotecan metabolic pathway","volume":"10","author":"Ma","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0090","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1002\/stem.187","article-title":"Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging","volume":"27","author":"Kidd","year":"2009","journal-title":"Stem Cells"},{"key":"10.1016\/j.jconrel.2019.09.006_bib0095","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19071930","article-title":"Recent progress in gene therapy for ovarian cancer","volume":"19","author":"Ayen","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0100","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jim.2009.06.008","article-title":"ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays","volume":"347","author":"Hu","year":"2009","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jconrel.2019.09.006_bib0105","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.addr.2015.05.009","article-title":"Progress and problems with the use of suicide genes for targeted cancer therapy","volume":"99","author":"Karjoo","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0110","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40495-016-0073-y","article-title":"Enzyme\/Prodrug Systems for Cancer Gene Therapy","volume":"2","author":"Malekshah","year":"2016","journal-title":"Curr. Pharmacol. Rep."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0115","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jconrel.2015.01.003","article-title":"Genetically engineered theranostic mesenchymal stem cells for the evaluation of the anticancer efficacy of enzyme\/prodrug systems","volume":"200","author":"Nouri","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.09.006_bib0120","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.biocel.2016.07.017","article-title":"Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines","volume":"78","author":"Januchowski","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2012.02.002","article-title":"Ovarian cancer stem cell markers: prognostic and therapeutic implications","volume":"322","author":"Burgos-Ojeda","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0130","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1471-2407-5-78","article-title":"Cancer cell adaptation to chemotherapy","volume":"5","author":"Di Nicolantonio","year":"2005","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2019.09.006_bib0135","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12885-016-2071-1","article-title":"Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines","volume":"16","author":"Jandu","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2019.09.006_bib0140","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1042\/CBI20100347","article-title":"Using ABCG2-molecule-expressing side population cells to identify cancer stem-like cells in a human ovarian cell line","volume":"35","author":"Dou","year":"2011","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0145","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2174\/1574888X11666160429122133","article-title":"Cell surface markers on adipose-derived stem cells: a systematic review","volume":"12","author":"Mildmay-White","year":"2017","journal-title":"Curr. Stem Cell Res. Ther."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0150","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1186\/s12885-017-3677-7","article-title":"A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice","volume":"17","author":"Aston","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2019.09.006_bib0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089527","article-title":"First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma","volume":"9","author":"Helland","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2019.09.006_bib0160","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/gt.2012.12","article-title":"Neural stem cell-mediated CE\/CPT-11 enzyme\/prodrug therapy in transgenic mouse model of intracerebellar medulloblastoma","volume":"20","author":"Gutova","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0165","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00280-010-1272-6","article-title":"Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding","volume":"67","author":"Choi","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0170","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3389\/fonc.2013.00076","article-title":"Cancer stem cells: a minor cancer subpopulation that redefines global cancer features","volume":"3","author":"Enderling","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107596","article-title":"Withaferin a alone and in combination with cisplatin suppresses growth and metastasis of ovarian cancer by targeting putative cancer stem cells","volume":"9","author":"Kakar","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2019.09.006_bib0180","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/MD.0000000000004764","article-title":"Cancer stem cells: understanding tumor hierarchy and heterogeneity","volume":"95","author":"Rich","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jconrel.2019.09.006_bib0185","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.mam.2013.06.002","article-title":"Ovarian cancer stem cells: molecular concepts and relevance as therapeutic targets","volume":"39","author":"Ahmed","year":"2014","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0190","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fonc.2013.00256","article-title":"Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research","volume":"3","author":"Ahmed","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0195","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.3892\/ol.2016.4937","article-title":"ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan","volume":"12","author":"Tuy","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0200","first-page":"917","article-title":"Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme\/prodrug therapy","volume":"5","author":"Danks","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0205","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1056\/NEJM198612253152606","article-title":"Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing","volume":"315","author":"Dvorak","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0210","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1634\/stemcells.2008-0141","article-title":"Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors","volume":"26","author":"Gutova","year":"2008","journal-title":"Stem Cells"},{"key":"10.1016\/j.jconrel.2019.09.006_bib0215","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3324\/haematol.10669","article-title":"Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD\/SCID mice","volume":"92","author":"Shi","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.jconrel.2019.09.006_bib0220","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1002\/stem.1198","article-title":"Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor-alpha-activated endothelial cells via both leukocyte-like and novel mechanisms","volume":"30","author":"Teo","year":"2012","journal-title":"Stem Cells"},{"key":"10.1016\/j.jconrel.2019.09.006_bib0225","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1002\/ijc.28455","article-title":"Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario","volume":"134","author":"Altaner","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2019.09.006_bib0230","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12885-015-1241-x","article-title":"Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I\/II clinical trial","volume":"15","author":"Niess","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jconrel.2019.09.006_bib0235","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jcyt.2012.10.003","article-title":"Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer","volume":"15","author":"Dembinski","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jconrel.2019.09.006_bib0240","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13287-016-0284-5","article-title":"Intraperitoneally infused human mesenchymal stem cells form aggregates with mouse immune cells and attach to peritoneal organs","volume":"7","author":"Bazhanov","year":"2016","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jconrel.2019.09.006_bib0245","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/stem.415","article-title":"Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma","volume":"28","author":"Pistollato","year":"2010","journal-title":"Stem Cells"},{"key":"10.1016\/j.jconrel.2019.09.006_bib0250","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1158\/1541-7786.MCR-08-0146","article-title":"Neural stem cell tropism to glioma: critical role of tumor hypoxia","volume":"6","author":"Zhao","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.jconrel.2019.09.006_bib0255","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/(SICI)1097-0215(19971210)73:6<891::AID-IJC22>3.0.CO;2-6","article-title":"Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma","volume":"73","author":"Jansen","year":"1997","journal-title":"Int. J. Cancer"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365919305395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365919305395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:44:52Z","timestamp":1759160692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365919305395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":51,"alternative-id":["S0168365919305395"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.09.006","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioengineered adipose-derived stem cells for targeted enzyme-prodrug therapy of ovarian cancer intraperitoneal metastasis","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}